Bayer’s Adempas meets primary endpoint in phase 4 trial in PAH patients
The German company said that 41% of PAH patients transitioning to Adempas therapy after inadequate response to phosphodiesterase-5 inhibitors (PDE5 inhibitors) achieved the composite primary endpoint, which is